Skip to main content

Tel. +49 89 210 98 60


11–14 September 2019 · Budapest Congress Center · Hungary

The Paediatric IBD Porto Group

Programme of PIBD 2019

The Paediatric IBD Porto Group of ESPGHAN has again created an impressing and stimulating scientific programme. For the first time a postgraduate course will be offered on Wednesday, 11 September 2019, focusing on basic and up-to date knowledge of Paediatric IBD. An overview about the Scientific Programme can be found here.

To take a detailed look at the Scientific Programme, find the daily schedule below.

Wednesday, 11 Sept 2019

13.30-16.30 Postgraduate Course

Basic and up-todate knowledge of Pediatric IBD (20min talk and 10min Discussion)

Chairs: Anne Griffiths (Canada), Salvatore Oliva (Italy)
13.30 Symptoms and signs Dániel Szücs (Hungary)
14.00 Lab, feces/FCP and US/MRI Kaija-Leena Kolho (Finland)
14.30 Upper- and lower endoscopy Sibylle Koletzko (Germany)
15.00 Coffee Break
15.30 Exclusive- and partial enteral nutrition Sanja Kolacek (Croatia)
16.00 Biologics: old and new drugs Stephan Buderus (Germany)

17.00 Opening Ceremony

Chair: Gábor Veres (Hungary)
Sanja Kolacek, President of ESPGHAN (Croatia)
Dan Turner, Head of Porto Group (Israel)
Raanan Shamir, Past President ESPGHAN (Israel)
Gábor Veres, President of PIBD 2019 (Hungary)

17.45-18.30 Are we successful in treating IBD in 2019 – Tandem Talk

Chair: Dan Turner (Israel)
17.45 How successful are we in treating IBD in 2019? Anne Griffiths (Canada)
18.05 Where do we fail and how can we improve? Michael Rosen (United States)
18.25 Discussion

Thursday, 12 Sept 2019

09.00-10.30 IBD across the globe: what can we learn from epidemiology, genetics, and environment

Chairs: Johan Van Limbergen (The Netherlands), Katalin Müller (Hungary)
09.00 How does PIBD epidemiology differ in the world? Eric Benchimol (Canada)
09.20 Using genetic/epigenetic research to understand the etiology of IBD David Wilson (United Kingdom)
09.40 Environmental Causes of IBD – learning from both the developing and developed worlds Eytan Wine (Canada)
10.00 Discussion
10.10 O-003 Clinical characteristics of Asian children with inflammatory bowel disease at diagnosis: data from a multi-centre Asian PIBD research network James Guoxian Huang (Singapore)
10.20 O-004 The phenotypic spectrum of IBD in Canadian-born children of South Asian ethnicity: a prospective multi-centre comparative inception cohort study MW Carroll (Canada)
10.30 Coffee Break

11.00-12.30 Immunology and Microbiome in IBD: how will this help my patients?

Chairs: András Arató (Hungary), Richard Kellermayer (United States)
11.00 Immune pathways in IBD and how they relate to current and future treatments Yael Haberman (Israel)
11.20 The immune-genetic basis of VEO-IBD Daniel Kotlarz (Germany)
11.40 Bugs are also biologics: can we change our microbes to treat IBD? Johan Van Limbergen (The Netherlands)
12.00 Discussion
12.10 O-005 Pro-inflammatory role of dietary fibers in IBD: defining how microbes shape the path to diet-associated inflammation, and guide diet-based therapies Heather Armstrong (Canada)
12.20 O-006 Fecal Short Chain Fatty Acids (SCFA) measurement and microbiome metabotype shifts in nutritional therapy of paediatric Crohn´s disease Johan van Limbergen (The Netherlands)

09.00-12.35 Parallel Course: Nurses and Dietitian's Session

find all details here

14.00-15.30 Global collaboration in PIBD

Chairs: Petar Mamula (United States), Gigi Veereman (Belgium)
14.00 Think big: International research and biobanks in PIBD Frank Ruemmele (France)
14.20 How can we adapt current guidelines to low-resource countries? Christina Hauer (Austria)

14.40-15.30 Lessons to learn from beyond Europe and North America

14.40 Treating PIBD in Asia Ben Kang (Korea)
15.00 Challenges of IBD management in TB endemic areas David Epstein (South-Africa)
15.20 Discussion
15.30 Coffee Break

16.00-17.35 Ulcerative Colitis - time for a Change?

Chairs: Amit Assa (Israel), Annamaria Staiano (Italy)
16.00 Should we revise our treatment paradigm in Ulcerative Colitis? Javier Martín de Carpi (Spain)
16.20 Implications of coexisting PSC and UC in children Peter Lewindon (Australia)
16.40 Practical management of post-colectomy complications Seamus Hussey (Ireland)
17.00 Discussion
17.15 O-007 Severe pediatric Ulcerative colitis is associated with decreased Infliximab post-induction trough levels and poor disease outcomes Massimo Martinelli (Italy)
17.25 O-008 Paediatric ulcerative colitis patients account for only 2% of total colectomy cases within a defined Scottish health board Christopher J. Burgess (United Kingdom)

Friday, 13 Sept 2019

9.00- 10.45 Crohn’s disease: beyond the tube

Chairs: Frank Rümmele (France), Sanja Kolacek (Croatia)
09.00 OMG, how can we treat OFG? Kaija-Leena Kolho (Finland)
09.20 Building a strong future: Bone health in IBD Francisco Sylvester (United States)
09.40 Growth impairment; prevention and management Richard Russell (United Kingdom)
10.00 Discussion
10.15 O-009 Patient-parents trio exome sequencing in early-onset primary sclerosing cholangitis identifies candidate genes involved in bile salt homeostasis and immunity P.F. van Rheenen (The Netherlands)
10.25 O-010 Validation of a new score for paediatric Crohn´s disease on a paediatric tertiary Hospital: The MINI-Index (Mucosal Inflammation Non-Invasive Index) Gemma Pujol Muncunill (Spain)
10.35 O-011 The effect of Adalimumab treatment on linear growth in children with Crohn´s disease: a post-hoc analysis of the PAILOT randomized control trial Manar Matar (Israel)
10.45 Coffee Break

11.15-12.45 Imaging and Endoscopy

Chairs: Marina Aloi (Italy), Javier Martin de Carpi (Spain)
11.15 Endoscopic and radiographic indices for P-IBD Gábor Veres (Hungary)
11.35 Endoscopic therapy in IBD Peter Mamula (United States)
11.55 Role of video capsule endoscopy in P-IBD Salvatore Oliva (Italy)
12.15 Discussion
12.25 O-012 Development of the PICMI – the paediatric inflammatory Crohn´s MRE Index: the ImageKids prospective study Gili Focht (Israel)
12.35 O-013 Quantified terminal ileal motility during MR enterography as a biomarker of Crohn’s Disease endoscopic activity in a paediatric population: A retrospective study Lucia Cococcioni (United Kingdom)

14.00-15.10 New directions in treating IBD or revisiting the old approaches

Chairs: András Tárnok (Hungary), David Wilson (United Kingdom)
14.00 New implications of dietary therapy in IBD Arie Levine (Israel)
14.20 Fecal transplantation in IBD Richard Kellermayer (United States)
14.40 Real efficacy of antibiotics in PIBD Victor Navas (Spain)
15.00 Discussion

15.10-16.20 Targets and Transition

Chairs: Áron Cseh (Hungary), Lissy de Ridder (The Netherlands)
15.10 Treating to what target? Marina Aloi (Italy)
15.30 Transition management: how, when, where? Hankje Escher (The Netherlands)
15.50 Discussion
16.00 It is all about them: Patient and Parent with IBD Rosie Campbell (United Kingdom)
16.20 Coffee Break

16.50-18.20 Biologics, small molecules and more

Chairs: Nicholas Croft (United Kingdom), Éva Nemes (Hungary)
16.50 Towards a real proactive use of biologics in our patients Amit Assa (Israel)
17.10 Small molecules on the horizon Jiri Bronsky (Czeck Republic)
17.30 The role of thalidomide and sirolimus in PIBD Holm Uhlig (United Kingdom)
17.50 Discussion
18.00 O-014 STEP-CD study: uSTEkinumab use in paediatric Crohn’s disease. A multicentre retrospective study from paediatric IBD Porto group of ESPGHAN Gemma Pujol-Muncunill (Spain)
18.10 O-015 Top-down infliximab superior to step-up in children with moderate-to-severe Crohn’s disease – a multicenter randomized controlled trial Maria Myrthe Elisabeth Jongsma (The Netherlands)

Saturday, 14 Sept 2019

9.00-10.00 Case presentations

Chair: Jorge Amil Dias (Portugal)
Jorge Amil Dias (Portugal)
Jaroslaw Kierkus (Poland)
Katalin Müller (Hungary)

10.00-11.15 Personalizing therapy and risks in our patients

Chairs: Jiri Bronsky (Czech Republic), Hankje Escher (The Netherlands)
10.00 Personalized treatment strategy in pediatric IBD Nick Croft (United Kingdom)
10.20 Cancer risk in pediatric patients with IBD Lissy de Ridder (The Netherlands)
10.40 Vaccination: “In-land and Ex-land” Gigi Veereman (Belgium)
11.00 Discussion
11.15 Coffee Break

11.45-12.25 Wrap-Up

Chairs: Dan Turner (Israel), Gábor Veres (Hungary)
11.45 Quality of care in inflammatory bowel diseases: What is the best way to better outcomes? Michael Kappelman (United States)
12.05 How to translate PIBD 2019 key messages into practice Dan Turner (Israel)

12.25-13.15 Closing Ceremony

Chair: David Wilson (United Kingdom)
12.25 Poster prizes
12.45 PIBD 2021
13.10 P-IBD Movie